The positive — most of the map

Outside the few large randomized cancer RCTs, the literature and patient narratives are predominantly positive: cells die, tumors shrink in animals, cases report stability and regression, real-world cohorts describe benefit, and early human studies show tolerability and occasional response.

That is why everyday conversation sounds “all positive”: that is what spreads in labs, forums and cases. The few formal “failures” are narrow, technical and rarely viral — short list at the bottom.

1. Preclinical (cells & animals) — massive positive volume

Ivermectin

Inhibits proliferation in breast, colon, ovarian, pancreas, kidney, gastric, lung, etc.
WNT/β-catenin, PAK1/Akt/mTOR, importin, YAP1, mitochondrial stress
Immunogenic cell death + anti-PD-1 synergy in mice
Synergy with gemcitabine, cisplatin, doxorubicin, paclitaxel, bortezomib

IVM page →

Fenbendazole

Microtubules + glucose/GLUT/HK II (Dogra 2018)
Effect in 5-FU-resistant colorectal cells (Korea)
Cervix, HCC, ovarian (nanoformulation), lung
Canine melanoma cells G2/M arrest

FBZ page →

Mebendazole

Johns Hopkins: GBM mice + up to ~63% survival gain
Colon, melanoma, lung, breast, prostate etc. in preclinical work
Angiogenesis / Hedgehog / tubulin — multi-target
ReDO project lists MBZ as repurposing candidate

MBZ page →

2. Human cases & real-world — positive tone

C Michigan 2011 — MBZ monotherapy
Metastatic adrenal cortical cancer: regression + 19 mo stability, good quality of life.
PubMed
B Johns Hopkins 2021 — phase I HGG
Safety to 200 mg/kg; median OS 21 mo; 41.7% at 2 years (n=24).
PMC
A Egypt — MBZ + FOLFOX/bev (mCRC)
Small RCT: higher ORR and longer PFS in MBZ arm (single-center).
NCT03925662
B Hulscher 2026 — IVM + MBZ cohort
High self-reported clinical benefit, high adherence, mostly mild side effects.
Anticancer Research
C Tippens + FBZ case series
Global patient movement; case series with reported responses (uncontrolled but consistently positive narrative).
USA page
B ASCO 2025 interim — IVM + ICI (TNBC)
Safe combination; 1 partial response in early cohort.
ASCO abstract

3. World — positive spread beyond “clinical western RCT”

China: large volumes of IVM & FBZ mechanism/cell studies
Korea: FBZ lab studies + huge patient interest
Japan: discovery of avermectins (Nobel)
India: formal MBZ studies in glioma
Latin America / Africa: mass experience of IVM/MBZ as safe generics (parasites) + patient self-use in cancer
Integrative practice: combinations with curcumin, CBD, vitamins, ketogenic diet — consistently positive patient discourse

World page → · USA page →

4. Pets — parasite pressure & caregiver burden

Less routine + shared runs → higher parasite pressure → more sick animals → caregiver burden in owners. Fenbendazole etc. remain central tools — especially for GI-sick animals and proven parasites — best as targeted treatment in a risk-based process.

Overview · Processes · Sources

5. Safety — what people actually experience

At approved parasite doses, IVM and MBZ have decades of “well tolerated” experience. Oncology cases and cohorts often describe mild GI effects; Gallia shows high MBZ doses can be given under monitoring.

6. Where are the negatives? (short, honest list)

You are right that they are few compared with the positive volume. What exists is mostly:

What	What it really means	Why you rarely “hear” it
Patil 2022 (India) — phase II recurrent GBM + MBZ	Missed a predefined OS target (both arms had MBZ — no pure “without MBZ” arm)	Technical endpoint; not a viral “it doesn’t work” headline. Patients tolerated MBZ.
Mansoori et al. — MBZ monotherapy refractory GI	No meaningful response in a small monotherapy study	Does not contradict combinations (e.g. Egypt FOLFOX+MBZ)
Occasional null preclinical (e.g. Duan FBZ 2013)	Some animal models do not respond — biological variation	Drowned by dozens of positive cell/animal papers
ASCO/ACS “advise against outside trials”	Policy on evidence level / standard of care — not a new negative lab study	Sounds “negative” but is bureaucracy, not contradiction of cell data
Liver enzymes at very high MBZ dose (Gallia)	Dose-dependent, often reversible — study still concluded “acceptable safety”	Routine labs, not “catastrophe”

Conclusion: the global map (lab + cases + real-world + early clinic) is predominantly positive. “Negative” in media/forums is almost invisible because it either does not exist in large volume, or is narrow study endpoints and institutional text — not “people got sick / tumors grew from it”.

Original sources Study table